Monday, 7 October 2024
  
Login

Australia's most trusted
source of pharma news

Monday, 07 October 2024
News

Aussie invention banks US$100M

Posted 26 September 2024 PM

London-based start-up Vicebio has raised US$100 million in Series B financing to continue developing the molecular clamp platform against life-threatening respiratory viral infections.

ViceBio, led by former GSK exec Emmanuel Hannon, was established in 2019 by investment firm Medicxi to develop novel vaccines using the University of Queensland's tech, which made headlines early in the Covid vaccine race.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (6)

Sales & Customer Relations (15)

Clinical & Medical, R&D (12)

Regulatory, Pharmacovigilance & QA (6)

Other (13)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.